Syncromune Granted FDA Fast-Track Designation for SYNC-T SV-102 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC)FORT LAUDERDALE, Fla., July 01, 2024 (GLOBE NEWSWIRE) -- Syncromune® Inc., a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for solid tumor cancers, today announced that the U.S. Food and Drug Administration (FDA) has...